Vincere Biosciences

virtual cell platform, mitochondrial repair, USP30

clearingsmall molecule

vincerebio.com·United States·$8M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-B1JI

Projects

Parkin E3 ligase activity assay program

exploratory

research program · medium

Enable high-throughput identification of small molecules that reinstate or boost Parkin activity as a potential Parkinson's disease treatment strategy.

Two complementary MALDI-TOF/MS-based assays for quantifying Parkin E3 ligase activity in vitro.

A 2024 publication reported scalable high-throughput primary screening assays for Parkin modulators.

The publication states that both MALDI-TOF/MS approaches are scalable for high-throughput primary screening.

USP30 mitochondrial repair program

preclinical

drug program · high

Develop new medicines targeting USP30-driven mitochondrial repair for age-related diseases including Parkinson's disease and kidney disease.

Therapeutic target program centered on USP30, identified through Vincere's virtual cell platform.

USP30 is listed as the company's prioritized pipeline target.

Virtual cell platform

exploratory

platform · high

Identify high-leverage therapeutic targets for age-related diseases including Parkinson's disease and kidney disease.

Integrates human genetics, cellular network models, and in-silico biology.

Platform has prioritized USP30 as a driver of mitochondrial repair and is supported by over $8 million in grant funding.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence